Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma

This study aims to compare the one-year survival benefit of the association of cryoablation-pembrolizumab-pemetrexed-carboplatin versus pembrolizumab-pemetrexed-carboplatin in metastatic lung adenocarcinoma patients. This is a multicenter, prospective, open-labeled, 2-arm comparative randomized (1:1) phase III trial. Patients will be randomized with a 1:1 ratio into: * Arm A (experimental arm): cryoablation of one visceral lesion or bone metastasis excluding liver and sclerotic bone metastases combined with pembrolizumab and pemetrexed-carboplatin prescribed as per market authorization. * A

Trial Details

NCT ID
NCT04339218
Phase
PHASE3
Sponsor
Institut Bergonié
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • Cryoablation
  • Pembrolizumab
  • Pemetrexed
  • Carboplatin
Locations (sample)
  • Bordeaux, Gironde, France|44.84124,-0.58046

Key Eligibility Criteria

  • Histologically or cytologically confirmed non-small lung adenocarcinoma.
  • Metastatic disease.
  • Treatment with pembrolizumab in combination with pemetrexed-carboplatin as per market authorization.
  • At least two target lesions (RECIST1.1), measurable with CT or MRI :

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →